Lapatinib: Its Uses in Cancer, Side Effects, and Risks

Lapatinib is a targeted therapy medication used to treat specific forms of cancer. Administered orally as a tablet, it is recognized by its brand names, Tykerb or Tyverb. This drug represents a modern approach to cancer treatment, focusing on the molecular characteristics of cancer cells. Unlike traditional chemotherapy that affects all rapidly dividing cells, lapatinib interferes with particular pathways that fuel cancer growth.

Medical Uses of Lapatinib

Lapatinib is authorized for treating certain types of breast cancer classified as HER2-positive. The term HER2-positive refers to cancer cells that have an excess of the human epidermal growth factor receptor 2 (HER2) gene. This genetic anomaly results in the overproduction of the HER2 protein, which acts as a receptor on the cell surface and promotes aggressive cell growth.

The medication is used for advanced or metastatic breast cancer, meaning the cancer has spread from the breast to other parts of the body. Its application is for patients whose cancer has progressed despite previous treatments with other therapies, including an anthracycline, a taxane, and trastuzumab.

Lapatinib is not used as a standalone treatment but is administered as part of a combination therapy. For patients with advanced or metastatic HER2-positive breast cancer, it is frequently prescribed alongside capecitabine, a chemotherapy drug. For postmenopausal women whose metastatic breast cancer is also hormone receptor-positive, lapatinib is used with letrozole, a type of hormone therapy.

Mechanism of Action

Lapatinib functions as a targeted drug known as a tyrosine kinase inhibitor. Its purpose is to interrupt communication signals inside cancer cells that command them to grow and multiply. It achieves this by targeting and binding to the intracellular portion of specific proteins called tyrosine kinases, which are important for cell signaling, effectively blocking their function.

The primary targets for lapatinib are two tyrosine kinases: the human epidermal growth factor receptor 2 (HER2) and the epidermal growth factor receptor (EGFR). Lapatinib obstructs the constant growth signal in HER2-positive cancers by preventing a process called autophosphorylation. This process acts as the “on” switch for the receptor’s activity.

By inhibiting both HER2 and EGFR, lapatinib provides a dual-action blockade. This action halts the downstream signaling cascades that would otherwise promote cell proliferation and survival. The interruption of these pathways can slow or stop the growth of tumors that rely on HER2 or EGFR activity.

Common Side Effects

Patients taking lapatinib may experience a range of side effects. Diarrhea is a very frequent side effect and was a primary reason for discontinuing the drug in clinical trials. It can range from mild to severe, and its management is an important part of treatment. Patients are advised to report any instances of diarrhea to their healthcare team for management strategies or dose adjustments.

Another common issue is a skin reaction known as hand-foot syndrome. This condition causes redness, swelling, and sometimes pain or blistering on the palms of the hands and soles of the feet. A general skin rash is also a frequent side effect. Careful skin care, including moisturization and avoiding harsh chemicals or sun exposure, can help manage these symptoms.

Fatigue and nausea are also regularly reported by individuals undergoing treatment with lapatinib. These feelings of tiredness and an upset stomach can impact daily activities. Some patients may develop mouth sores, which can cause discomfort and difficulty eating. Communicating these side effects to a doctor allows for interventions like anti-nausea medication or dietary changes.

Serious Risks and Precautions

Lapatinib carries a black box warning from the U.S. Food and Drug Administration concerning the risk of severe liver injury (hepatotoxicity). This is the most serious warning issued for a medication and indicates a potential for significant harm. Liver problems can be severe and sometimes fatal. Patients must be monitored for signs of liver damage, including jaundice, dark urine, unusual fatigue, or pain in the upper right abdomen.

The medication can also affect heart function. It has been associated with a decrease in the heart’s ability to pump blood effectively, a condition measured as a reduced left ventricular ejection fraction. Another cardiac issue is the prolongation of the QT interval, an electrical event in the heart that can lead to an abnormal heartbeat. Symptoms like a racing heart, shortness of breath, or ankle swelling should be reported to a physician.

Severe diarrhea is another significant risk. While common, diarrhea can become severe enough to cause dehydration and other complications that may require hospitalization. If diarrhea becomes severe, treatment with lapatinib may need to be interrupted or stopped. Careful monitoring by a healthcare professional is a standard part of the treatment protocol.

Certain precautions must be taken while on lapatinib. The drug can interact with many other medications, so patients should inform their doctor of all medications they are taking, including over-the-counter drugs and supplements. It is also necessary to avoid grapefruit and grapefruit juice, as they can interfere with the metabolism of lapatinib and increase its concentration in the body, heightening the risk of side effects.

Prostate Volume Calculator: The Cheng Formula Explained

What Is a MACE Score and How Is It Used?

Female Hypogonadism: Causes, Symptoms, and Treatment